BEAM - Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics

2024-04-30 13:25:04 ET

Summary

• CRISPR/Cas9 technology allows for precise editing of DNA, potentially treating human diseases by replacing entire genes.
• CRISPR Therapeutics has developed the first FDA-approved ex vivo CRISPR/Cas9 therapy, Casgevy, for sickle cell disease and transfusion-dependent beta-thalassemia.
• The market seems pessimistic about the commercialization of these therapies, but if successful, CRISPR Therapeutics could generate significant shareholder value, perhaps nearly equal to the Enterprise Value of the company.
• Furthermore, CRSP's technology platform may present significant further shareholder value.
• CRSP is a best-in-breed biotech, a must own for those believing that CRISPR/Cas9 will lead to disruptive innovation in the healthcare space.

As investors search for disruptive companies within the biotech sector, it is helpful to consider disruptive technologies that necessarily precede them. Specifically, the revolutionary CRISPR/Cas9 gene-editing platform has recently made headlines with FDA approval of a revolutionary drug named Casgevy. This therapy, pioneered by CRISPR Therapeutics (NASDAQ: CRSP), amazingly recognizes the correct segment of DNA to edit by using a piece of RNA as a guide....

For further details see: